Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
79P - Small cell lung cancer in the young: Characteristics, timeliness and outcome data (ID 334)
12:30 - 13:00 | Author(s): J. Li
Patients with small cell lung cancer (SCLC) younger than 40 are limited in number and are understudied. Our research aimed to assess the characteristics, timeliness of cancer development, and outcomes of this patient population.
Records of Patients under the age of 40 with SCLC at the Chinese Academy of Medical Sciences between January 2006 and December 2015 were reviewed and evaluated.
One hundred and three patients (67.0% limited-stage, 33.0% extensive-stage) were included, along with 54 (52.4%) never-smokers. The median duration of the diagnostic interval and the median survival time (MST) were 51.0 days and 24.0 months, respectively. Survival was significantly better for limited-stage patients than for those in the extensive-stage group (MST, 28.0 vs. 14.0 months, p < 0.0001). Patients with shorter diagnostic times (≤1 month) tended to have a better prognosis than those with a longer delay to diagnosis (MST, 25.0 vs. 23.0 months, p = 0.061), which was more pronounced in the limited stage group (MST, 48.0 vs. 26.0 months, p = 0.043). A timely diagnosis also exerted a positive impact on progression-free survival (PFS) in both the limited-staged patients (36.0 vs. 13.0 months, p = 0.061) and extensive-staged patients (6.0 vs. 3.0 months, p = 0.047). Further analysis identified a correlation between the antibiotic treatment before SCLC diagnosis and the diagnostic interval (Spearman Rho = 0.294, p = 0.003). Multivariate analysis suggested that empirical antibiotherapy history, disease stage, and tumor location independently correlated with survival.
Our study identified distinct characteristics of patients with SCLC under 40. More timely care could improve patient outcomes especially among those at a limited-stage.
Clinical trial identification:
Legal entity responsible for the study:
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Has not received any funding
All authors have declared no conflicts of interest.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.